MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of esc…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | $-0.23 | $-0.56 | $-0.24 |
| Estimado | $-0.77 | $-0.66 | $-0.61 | $-0.83 |
| Sorpresa | — | +65.2% | +8.2% | +71.1% |
| Métrica | MDWD | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 19.2% | 57.4% | -38.2% |
| Operating Margin | -149.0% | -34.4% | -114.6% |
| Net Margin | -140.8% | -32.5% | -108.4% |
| FCF Margin | -127.5% | -12.6% | -114.9% |
| ROE | -54.7% | -39.2% | -15.6% |
| ROA | -27.7% | -30.9% | +3.3% |
| Current Ratio | 2.33 | 2.73 | -0.40 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -27.7% | — |
| ✗Flujo de caja operativo positivo | −$16M | −$14M |
| ✓Rentabilidad sobre activos al alza | -27.7% | -41.1% |
| ✓Caja operativa/activos supera al ROA | -18.7% | ROA -27.7% |
| –Menos deuda a largo plazo | — | — |
| ✓Mejor liquidez (ratio corriente) | 2.33 | 1.97 |
| ✗Sin aumentar el nº de acciones | 11M | 10M |
| ✓Margen bruto al alza | 19.2% | 13.0% |
| ✗Rotación de activos al alza | 0.20 | 0.28 |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | -127.5% |
| ✗ROCE > 10 % | -41.7% |
| ✗Ventas > 5 %/año (3 años) | -13.8% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 116.9% |
MediWound Ltd. cotiza a 11.85 USD y tiene una capitalización bursátil de $153M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud